NanoViricides Highlights NV-387 as Key Measles Solution Amid Rising Cases

NanoViricides, Inc., a firm listed on the NYSE American, emphasized the necessity of its drug candidate NV-387 to tackle increasing measles cases globally. As reported, the United States, Canada, the UK, and the European Union are witnessing significant upsurges in measles cases.

NV-387 has demonstrated safety and efficacy in animal studies and has completed a Phase I clinical trial without adverse events. NanoViricides aims to expedite its development under US FDA programs, potentially benefiting from Orphan Drug Designation.

Currently, measles outbreaks pose a notable concern as the disease can diminish a person's acquired immunity, affecting both vaccinated individuals and those recovering from other infections. Public health data shows the disease's transmission has surged, with measles cases reported globally each year.

With the persistence of measles threats and rising vaccine hesitancy, NanoViricides believes NV-387 can fulfill an essential need in treating and preventing the disease's spread.